Dose Reduction of IL17 and IL23 Inhibitors in Psoriasis
- Status
- COMPLETED
- Phase
- PHASE4
Clinical Trials Related to Risankizumab
Related studies linked through entity extraction aliases.
A Study to Evaluate the Effect of Intravenous (IV) Infusions of Risankizumab on Pharmacokinetics of Cytochome P450 Substrates in Adult Participants With Moderately to Severely Active Ulcerative Colitis or Crohn's Disease
- Status
- COMPLETED
- Phase
- PHASE1
A Study of the Safety and Efficacy of Risankizumab in Adult Participants With Plaque Psoriasis Who Have Had a Suboptimal Response to Secukinumab or Ixekizumab
- Status
- COMPLETED
- Phase
- PHASE3
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
- Status
- COMPLETED
- Phase
- PHASE2
Expanded Access to Risankizumab
- Status
- NO_LONGER_AVAILABLE
- Phase
- N/A
A Study to Assess Usability of Risankizumab Autoinjector Combination Product in Participants With Moderate to Severe Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Assess Safety and Efficacy of Risankizumab Using a New Formulation in Participants With Moderate to Severe Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Evaluate Risankizumab in Adults and Adolescents With Moderate to Severe Atopic Dermatitis
- Status
- COMPLETED
- Phase
- PHASE2
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies)
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
Risankizumab Therapy Versus Placebo for Subjects With Psoriasis in the Russian Federation
- Status
- COMPLETED
- Phase
- PHASE3
Risankizumab Versus Secukinumab for Participants With Moderate to Severe Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Assess the Efficacy and Safety of Risankizumab in Participants With Ulcerative Colitis
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE3
A Study to Assess the Efficacy of Risankizumab Compared to FUMADERM® in Subjects With Moderate to Severe Plaque Psoriasis Who Are Naïve to and Candidates for Systemic Therapy
- Status
- COMPLETED
- Phase
- PHASE3
A Study Comparing the Safety and Efficacy of Risankizumab to Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Assess the Safety and Efficacy of Risankizumab for Maintenance in Moderate to Severe Plaque Type Psoriasis ( LIMMITLESS )
- Status
- COMPLETED
- Phase
- PHASE3
A Study to Assess Efficacy and Safety of Two Different Dose Regimens of Risankizumab Administered Subcutaneously in Japanese Subjects With Generalized Pustular Psoriasis or Erythrodermic Psoriasis
- Status
- COMPLETED
- Phase
- PHASE3
BI 655066 (Risankizumab) Compared to Placebo in Japanese Patients With Moderate to Severe Chronic Plaque Psoriasis
- Status
- COMPLETED
- Phase
- PHASE2
A Study to Investigate Safety With Risankizumab in Psoriatic Arthritis Subjects Who Have Completed Week 24 Visit of Study M16-002 (NCT02719171)
- Status
- COMPLETED
- Phase
- PHASE2
This Study Tests the Effect of Risankizumab on the Metabolism in the Liver of Five Additional Drugs to Study Possible Drug Interactions in Patients With Psoriasis With or Without Psoriatic Arthritis
- Status
- COMPLETED
- Phase
- PHASE1